RxDoctor Payments Data

Eric Simpson, MD

Dermatology · Portland, ORNPI 1972511426

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Sanofi at 27.9% of the total. Among dermatology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,399,702in general payments, 2019–2025

Across 879 payments — averaging $1592.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$390K
  • Pfizer$237K
  • Sanofi-aventis U.S. LLC$139K
  • Eli Lilly$134K
  • LEO Pharma AS$118K
  • AbbVie$61K
  • plus $320K from 25 others
$3,821,943in research payments, 2019–2025

Across 1,842 payments — averaging $2074.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1.3M
  • AbbVie$552K
  • Pfizer$511K
  • Eli Lilly$411K
  • Incyte Corporation$231K
  • Arcutis Biotherapeutics, Inc.$224K
  • plus $557K from 12 others

What the payments were for

  • Consulting fees$781,42756%
  • Speaking & faculty fees$478,92634%
  • Grants$1,0000%
  • Travel & lodging$132,2949%
  • Food & beverage$5,9500%
  • Education$1050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,399,702 in reported general payments places this provider in the 95th percentile of 175 dermatology providers in Oregon.

See all dermatology providers in Oregon

Medicare billing

Part B allowed, 2024
$63,530
Medicare patients
403
Services billed
1,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab63$234,750
Dupixent SyringeDupilumab34$130,667
Tacrolimus37$4,518
Clobetasol Propionate42$910
Triamcinolone Acetonide49$651
MethotrexateMethotrexate Sodium20$323
Hydrocortisone13$148

Paid to pharmacies, not to this prescriber.

Other dermatology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →